Because Alzheimer’s disease is such a serious concern for seniors, any advocacy group’s recommendations for a drug company’s proposed therapy must be science-based and above reproach, says Leslie Norins, MD, PhD, FIDSA, CEO of Alzheimer’s Germ Quest.
On January 29, the FDA granted Biogen an extension, until June 7, to add to or recalculate existing data for its candidate drug, aducanumab.
Concurrently, the CEO of the Alzheimer’s Association (AA), Harry Johns, issued to its executives, supporters, and others a national e-letter endorsing the compound, saying in it, “We believe the publicly released scientific data..” However, he offered no details, or a reference, as to how, and by whom, his organization arrived at a conclusion different from that of the FDA expert advisory committee, which voted 10 to one against approval of the drug in…
